Additionally, ZNF433 is significantly upregulated in prostate cancer, where it promotes cancer cell proliferation, migration, and tumorigenicity by activating the β-catenin/TCF signaling pathway, making it a potential therapeutic target for prostate cancer (17). The gene discussed is HNF4A; the disease is prostate carcinoma.